{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"Recommended safe dose of moxetumomab pasudotox-tdfk is defined as the treatment of 10 participants with no more than 2 experiencing a dose-limiting toxicity (DLT). A DLT is defined as all treatment related Grade 3-5 adverse events (AEs) occurring from the initiation of moxetumomab pasudotox-tdfk therapy to within 30 days after the last dose of moxetumomab pasudotox-tdfk treatment assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). Grade 3 is severe, Grade 4 is life-threatening, and Grade 5 is death related to adverse event.","groups":[{"description":"All participants in Group 1 and Group 2 who received at least one dose of Moxetumomab 30-40 mcg/kg.","id":"OG000","title":"All Participants"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"4 weeks","title":"Recommended Safe Dose of Moxetumomab Pasudotox-tdfk","type":"PRIMARY","unitOfMeasure":"mcg/kg"}